Masimo to Report First Quarter 2024 Financial Results after Market Close on Tuesday, May 7
2024年4月23日 - 9:00PM
ビジネスワイヤ(英語)
Conference call and webcast to begin at 1:30
p.m. PT (4:30 p.m. ET)
Masimo (NASDAQ: MASI) will release first quarter 2024 financial
results for the period ended March 30, 2024, after the market
closes on Tuesday, May 7, 2024. The conference call to review the
results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be
hosted by Joe Kiani, Chairman and Chief Executive Officer, and
Micah Young, Executive Vice President and Chief Financial
Officer.
To register for the conference call and receive the dial-in
number, please use the link below. Upon registering, each
participant will be provided with details including the dial-in
number and a registrant ID number. Reminders about the call will
also be sent to registered participants via email.
Conference Call Registration Link (Please register to obtain
the dial-in number):
https://registrations.events/direct/Q4I407288
A replay of the webcast and conference call will be available
shortly after the conclusion of the call and will be archived on
the Company’s website.
About Masimo
Masimo (NASDAQ: MASI) is a global medical technology company
that develops and produces a wide array of industry-leading
monitoring technologies, including innovative measurements,
sensors, patient monitors, and automation and connectivity
solutions. In addition, Masimo Consumer Audio is home to eight
legendary audio brands, including Bowers & Wilkins, Denon,
Marantz, and Polk Audio. Our mission is to improve life, improve
patient outcomes, and reduce the cost of care. Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry,
introduced in 1995, has been shown in over 100 independent and
objective studies to outperform other pulse oximetry technologies.2
Masimo SET® has also been shown to help clinicians reduce severe
retinopathy of prematurity in neonates,5 improve CCHD screening in
newborns,6 and, when used for continuous monitoring with Masimo
Patient SafetyNet™ in post-surgical wards, reduce rapid response
team activations, ICU transfers, and costs.7-10 Masimo SET® is
estimated to be used on more than 200 million patients in leading
hospitals and other healthcare settings around the world,3 and is
the primary pulse oximetry at 9 of the top 10 hospitals as ranked
in the 2022-23 U.S. News and World Report Best Hospitals Honor
Roll.4 In 2005, Masimo introduced rainbow® Pulse CO-Oximetry
technology, allowing noninvasive and continuous monitoring of blood
constituents that previously could only be measured invasively,
including total hemoglobin (SpHb®), oxygen content (SpOC™),
carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth
Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve
Index (ORi™). In 2013, Masimo introduced the Root® Patient
Monitoring and Connectivity Platform, built from the ground up to
be as flexible and expandable as possible to facilitate the
addition of other Masimo and third-party monitoring technologies;
key Masimo additions include Next Generation SedLine® Brain
Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography
with NomoLine® sampling lines. Masimo’s family of continuous and
spot-check monitoring Pulse CO-Oximeters® includes devices designed
for use in a variety of clinical and non-clinical scenarios,
including tetherless, wearable technology, such as Radius-7®,
Radius PPG®, and Radius VSM™, portable devices like Rad-67®,
fingertip pulse oximeters like MightySat® Rx, and devices available
for use both in the hospital and at home, such as Rad-97®. Masimo
hospital and home automation and connectivity solutions are
centered around the Masimo Hospital Automation™ platform, and
include Iris® Gateway, iSirona™, Patient SafetyNet, Replica®, Halo
ION®, UniView®, UniView :60™, and Masimo SafetyNet®. Its growing
portfolio of health and wellness solutions includes Radius T°® and
the Masimo W1™ watch. Additional information about Masimo and its
products may be found at www.masimo.com. Published clinical studies
on Masimo products can be found at
www.masimo.com/evidence/featured-studies/feature.
ORi, RPVi, and Radius VSM have not received FDA 510(k) clearance
and are not available for sale in the United States. The use of the
trademark Patient SafetyNet is under license from University
HealthSystem Consortium.
Masimo, SET, Signal Extraction Technology,
Improving Patient Outcome and Reducing Cost of Care by Taking
Noninvasive Monitoring to New Sites and Applications, rainbow,
SpHb, SpOC, SpCO, SpMet, PVI are trademarks or registered
trademarks of Masimo.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240423575193/en/
Investor Contact: Eli Kammerman (949) 297-7077
ekammerman@masimo.com
Media Contact: Evan Lamb (949) 297-3376
elamb@masimo.com
Masimo (NASDAQ:MASI)
過去 株価チャート
から 4 2024 まで 5 2024
Masimo (NASDAQ:MASI)
過去 株価チャート
から 5 2023 まで 5 2024